Publication | Closed Access

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Open LabelWeek 96Treatment And PreventionGlobal HealthAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyPharmacotherapyNon-inferiority TrialChronic Viral InfectionAntiviral DrugHivMedicine